Which Weight Management Treatment Offers Better Value?
Understanding Ozempic vs Mounjaro vs Wegovy Cost for Weight Management
When evaluating Ozempic vs Mounjaro vs Wegovy cost, it's crucial to understand that only Wegovy and Mounjaro are licensed for weight management in the UK. Ozempic contains the same active ingredient as Wegovy (semaglutide) but is exclusively licensed for type 2 diabetes treatment. Wegovy operates as a GLP-1 receptor agonist, mimicking natural fullness hormones to reduce appetite and promote satiety after smaller meals. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist that targets multiple metabolic pathways simultaneously.
The cost comparison between these treatments reveals significant differences in pricing structures and dose escalation requirements. Wegovy requires five dose increases from 0.25mg to 2.4mg maintenance, whilst Mounjaro follows six dose escalations from 2.5mg to 15mg. Both prescription-only medicines require clinical assessment and ongoing prescriber supervision throughout treatment. Understanding these fundamental differences helps patients make informed decisions about long-term treatment costs and clinical suitability.
Complete Wegovy vs Mounjaro Pricing Breakdown and Value Analysis
When comparing Ozempic vs Mounjaro vs Wegovy cost structures, Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to 2.4mg maintenance (£209.99). Our bundle options provide convenient supply management, including the Intro Trio (0.25mg, 0.5mg & 1mg) for £299.99 and Ultimate Stability Trio (2.4mg ×3) for £649.99. New customers benefit from discount code FIRST40, whilst returning customers use DOSE25, both applied automatically at checkout. These bundles offer Reliable Supply continuity rather than cost savings, ensuring uninterrupted treatment progression.
Mounjaro follows a different pricing and dosing structure, making direct cost comparison complex without considering individual clinical needs. The choice between treatments should factor in mechanism of action, with Wegovy's proven GLP-1 approach versus Mounjaro's dual hormone targeting. Our GPhC-registered pharmacy (#9012878) provides transparent pricing for both options, allowing patients and prescribers to evaluate total treatment costs across different dose escalation timelines. Both treatments require prescription-only medicine status and cannot be purchased without appropriate clinical assessment.
Clinical Evidence Comparing Weight Management Outcomes
Clinical trials demonstrate that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the landmark STEP 1 trial (Wilding et al., NEJM, 2021). The STEP programme encompassed multiple studies, with STEP 2 showing clinically studied weight loss in patients with type 2 diabetes, whilst STEP 3 achieved clinically studied weight loss when combined with intensive behavioural therapy. These results represent averages from controlled trial conditions and individual outcomes may vary significantly.
Mounjaro clinical trials used different study designs and patient populations, making direct comparison of weight loss percentages inappropriate and potentially misleading. Both treatments demonstrated cardiovascular benefits in their respective trials, with Wegovy's SELECT study showing 20% reduction in major cardiovascular events. The choice between treatments should be based on individual clinical factors rather than trial comparisons, as different mechanisms may suit different metabolic profiles and health conditions.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1, a naturally occurring hormone released after eating. This mechanism reduces appetite by acting on brain appetite centres, promoting feelings of fullness after smaller meals and potentially reducing food cravings throughout the day. The once-weekly injection using Novo Nordisk's FlexTouch pen system provides consistent hormone levels, supporting sustainable eating pattern changes. Wegovy must be used alongside a reduced-calorie diet and increased physical activity, as the medication enhances but doesn't replace lifestyle modifications. The GLP-1 mechanism also slows gastric emptying, helping patients feel satisfied with smaller portion sizes whilst supporting long-term weight management goals.
Streamlined Ordering Process and Clinical Assessment
EverydayMeds provides a comprehensive three-minute online clinical assessment covering medical history, current medications, and weight management goals to determine treatment suitability. Our qualified prescribers review each assessment within three working days (24-hour express option available), ensuring appropriate clinical oversight for this prescription-only medicine. Once approved, we arrange next-day delivery using temperature-controlled cold-chain logistics to maintain medication efficacy throughout transport. The assessment process evaluates contraindications, potential drug interactions, and individual clinical factors that influence treatment selection between Wegovy and Mounjaro. Our GPhC-registered pharmacy service (#9012878) ensures full regulatory compliance whilst providing convenient access to licensed weight management treatments.
Storage Requirements and Practical Treatment Considerations
Wegovy requires refrigeration at 2-8°C before first use but offers significant storage flexibility with up to six weeks at room temperature below 30°C once removed from the fridge. This storage advantage over Mounjaro's 21-day room temperature limit makes Wegovy particularly suitable for frequent travellers or those with variable schedules. The FlexTouch pen system provides pre-measured doses with clear visual confirmation of injection completion, whilst the mandatory dose escalation schedule prevents rapid dose increases that might cause adverse effects. Each pen contains four doses, requiring one injection weekly on the same day each week, with injection sites rotated between thigh, abdomen, or upper arm. Proper storage and injection technique training support treatment success and reduce the risk of medication degradation or injection-site reactions.
Wegovy vs Mounjaro: Mechanism Differences and Clinical Considerations
The fundamental difference when evaluating Ozempic vs Mounjaro vs Wegovy cost lies in understanding that Wegovy targets GLP-1 receptors exclusively, whilst Mounjaro activates both GIP and GLP-1 receptors through its tirzepatide formulation. This dual mechanism may offer different metabolic effects, though individual response varies significantly between patients. Wegovy's established GLP-1 pathway provides predictable appetite reduction and satiety enhancement, making it suitable for patients seeking proven single-hormone targeting.
Cost considerations must include the different dose escalation schedules, with Wegovy requiring five dose increases versus Mounjaro's six-dose progression to maximum therapeutic levels. Some patients may find Wegovy's storage flexibility and established clinical profile more suitable for their lifestyle and treatment preferences. Both treatments are available through EverydayMeds with identical clinical assessment and prescriber review processes, ensuring appropriate treatment selection based on individual health profiles rather than cost alone.
Start Your Weight Management Journey Today
Both Wegovy and Mounjaro are available through EverydayMeds with transparent pricing and comprehensive clinical support throughout your treatment journey. New customers can apply discount code FIRST40 at checkout, whilst returning customers use DOSE25, both automatically calculated to reach our advertised prices. Our qualified prescribers can help determine which treatment mechanism—Wegovy's GLP-1 targeting or Mounjaro's dual hormone approach—best suits your individual clinical needs and lifestyle requirements. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and explore both treatment options with expert guidance. Remember that sustainable weight management requires commitment to dietary changes and increased physical activity alongside medication therapy.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
